Disease understanding in patients newly diagnosed with atrial fibrillation
View/ Open
Author
Kaufman, Brystana G
Kim, Sunghee
Pieper, Karen
Allen, Larry A
Gersh, Bernard J
Naccarelli, Gerald V
Ezekowitz, Michael D
Fonarow, Gregg C
Mahaffey, Kenneth W
Chan, Paul S
Freeman, James V
Ansell, Jack
Kowey, Peter R
Rieffel, James A
Piccini, Jonathan
Peterson, Eric
O’Brien, Emily C
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1136/heartjnl-2017-311800Metadata
Show full item recordCitation
Kaufman, B. G., S. Kim, K. Pieper, L. A. Allen, B. J. Gersh, G. V. Naccarelli, M. D. Ezekowitz, et al. 2018. “Disease understanding in patients newly diagnosed with atrial fibrillation.” Heart 104 (6): 494-501. doi:10.1136/heartjnl-2017-311800. http://dx.doi.org/10.1136/heartjnl-2017-311800.Abstract
Objective: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understanding of therapies at baseline and treatment receipt at 6 months among treatment-naïve patients. Methods: We analysed survey data from SATELLITE (Survey of Patient Knowledge and Personal Priorities for Treatment), a substudy of patients with new-onset AF enrolled in the national Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT) II registry across 56 US sites. Patients were surveyed at the baseline and 6-month follow-up clinic visits using Likert scales. Results: Among 1004 baseline survey responses, patients’ confidence in their understanding of rhythm control, ablation, anticoagulation and cardioversion was suboptimal, with ‘high’ understanding ranging from 8.5% for left atrial appendage closure to 71.3% for rhythm therapy. Of medical history and demographic factors, education level was the strongest predictor of reporting ‘high’ disease understanding. Among the 786 patients with 6-month survey data, significant increases in the proportion reporting high understanding were observed (p<0.05) only for warfarin and direct oral anticoagulants (DOACs). With the exception of ablation, high understanding for a given therapeutic option was not associated with increased use of that therapy at 6 months. Conclusions: About half of patients with new-onset AF understood the benefits of oral anticoagulant at the time of diagnosis and understanding improved over the first 6 months. However, understanding of AF treatment remains suboptimal at 6 months. Our results suggest a need for ongoing patient education. Clinical trial registration Clinicaltrials.gov. Identifier: NCT01701817.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861387/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:35982158
Collections
- HMS Scholarly Articles [17922]
- SPH Scholarly Articles [6362]
Contact administrator regarding this item (to report mistakes or request changes)